SCHEMBL3875583

SCHEMBL3875583

O=C(NCc1cccc(O)c1)c1ccc(C(=O)N[C@@H](CNC(=O)c2cc(Cl)cc(Cl)c2)C(=O)O)c(Cl)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
PLA2G1B P04054 1/20 0.45
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45
GAA P10253 1/20 0.45
CYP2D6 P10635 1/20 0.45
CYP2C19 P33261 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
ATG4B Q9Y4P1 1/20 0.45
ITGB1 P05556 2/20 0.44
ITGA4 P13612 2/20 0.44
ROCK2 O75116 1/20 0.43
ROCK1 Q13464 1/20 0.43
ACLY P53396 1/20 0.41
GRN P28799 2/20 0.41
SORT1 Q99523 2/20 0.41
ITGAL P20701 1/20 0.41
MT-CO2 P00403 1/20 0.41
ITGB7 P26010 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3876360 0.94 NPC1 (0.45) MEN1KMT2ACYP1A2CYP2D6CYP2C19
SCHEMBL3876648 0.94 ITGB1 (0.47) MEN1KMT2AITGB1ITGA4ROCK2
SCHEMBL3877125 0.94 MEN1 (0.42) MEN1KMT2APLA2G1BCYP1A2CYP3A4
SCHEMBL3869887 0.93 ROCK2 (0.46) ITGB1ITGA4ROCK2ROCK1ITGAL
SCHEMBL3866963 0.93 ITGB1 (0.45) MEN1KMT2AITGB1ITGA4ROCK2
SCHEMBL3866004 0.93 ITGB1 (0.46) MEN1KMT2AITGB1ITGA4ROCK2
SCHEMBL12361222 0.92 ROCK2 (0.47) MEN1KMT2AITGB1ITGA4ROCK2
SCHEMBL3866516 0.92 ROCK2 (0.47) MEN1KMT2AITGB1ITGA4ROCK2
SCHEMBL3871876 0.91 PPARG (0.45) MEN1KMT2AGAAITGB1ITGA4
SCHEMBL13940928 0.91 ITGB1 (0.43) MEN1KMT2AITGB1ITGA4ROCK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6803384-B2 FOR THERAPY OF REPERFUSION INJURY HOFFMANN-LA ROCHE INC. 2004-10-12 US claimed
US-20040006236-A1 Diaminopropionic acid derivatives FOTOUHI NADER (US) 2004-01-08 US claimed
US-20020052512-A1 Diaminopropionic acid derivatives FOTOUHI NADER (US) 2002-05-02 US claimed
US-7491741-B2 Diaminopropionic acid derivatives HOFFMANN-LA ROCHE INC. (US) 2009-02-17 US disclosed
US-20070155671-A1 Diaminopropionic acid derivatives FOTOUHI NADER 2007-07-05 US disclosed
US-7217728-B2 Diaminopropionic acid derivatives HOFFMANN-LA ROCHE INC. (US) 2007-05-15 US disclosed
US-20050080119-A1 Diaminopropionic acid derivatives FOTOUHI NADER (US) 2005-04-14 US disclosed
US-6803384-B2 FOR THERAPY OF REPERFUSION INJURY HOFFMANN-LA ROCHE INC. 2004-10-12 US disclosed
US-20040006236-A1 Diaminopropionic acid derivatives FOTOUHI NADER (US) 2004-01-08 US disclosed
US-20020052512-A1 Diaminopropionic acid derivatives FOTOUHI NADER (US) 2002-05-02 US disclosed
US-6331640-B1 TREATMENT OF REPERFUSION INJURIES HOFFMANN-LA ROCHE INC. 2001-12-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040006236-A1 Diaminopropionic acid derivatives AIFM1, AIFM2, HIF1A MEN1 4444/4885KMT2A 3790/4885PLA2G1B 998/4885
US-20020052512-A1 Diaminopropionic acid derivatives AIFM1, AIFM2, HIF1A MEN1 4444/4885KMT2A 3790/4885PLA2G1B 998/4885
US-20070155671-A1 Diaminopropionic acid derivatives AIFM1, HIF1A, AIFM2 MEN1 4739/4885KMT2A 4000/4885PLA2G1B 873/4885
US-20050080119-A1 Diaminopropionic acid derivatives AIFM1, HIF1A, AIFM2 MEN1 4739/4885KMT2A 4000/4885PLA2G1B 873/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.